Drug Effectiveness Review Project: Difference between revisions
CSV import |
CSV import |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 25: | Line 25: | ||
[[Category:Healthcare quality]] | [[Category:Healthcare quality]] | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | |||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 09:49, 17 March 2025
Drug Effectiveness Review Project (often abbreviated as DERP) is a collaborative program of evidence-based practice centers which produces comprehensive, unbiased reviews of the comparative effectiveness of commonly used drugs for treating medical conditions. The project was initiated in 2003 by a consortium of state Medicaid agencies in the United States, led by the Oregon Health & Science University (OHSU).
Overview[edit]
The Drug Effectiveness Review Project aims to provide objective, detailed analysis of the effectiveness, safety, and adverse effects of different drugs used in the treatment of a specific condition. The project's reports are used by participating organizations to inform policy decisions and develop clinical practice guidelines.
Methodology[edit]
The DERP uses a systematic review process to evaluate the existing scientific literature on a specific drug or class of drugs. This process includes the identification, selection, and appraisal of all relevant studies, followed by a synthesis of the collected data. The project's methodology is based on the principles of evidence-based medicine, which emphasizes the use of high-quality, randomized controlled trials.
Impact[edit]
The findings of the DERP have been used to inform drug policy decisions and clinical practice guidelines in several states. The project's reports have also been cited in the scientific literature and have contributed to the evidence base for comparative effectiveness research.
Criticism[edit]
While the DERP has been praised for its rigorous methodology and its contribution to evidence-based medicine, it has also faced criticism. Some critics argue that the project's focus on comparative effectiveness may overlook important differences between individual patients and their responses to treatment.
See also[edit]
References[edit]
<references />
